MUC1 is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

• Published in: Breast cancer research and treatment 2009-11, Vol.118 (1), p.113-124
• Main Authors: Fessler, Shawn P, Wotkowicz, Mark T, Mahanta, Sanjeev K, Bamdad, Cynthia
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal, Humanized; Antineoplastic Agents - pharmacology; Biological and medical sciences; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer research; Cancer therapies; Cell Line, Tumor - drug effects; Cell Line, Tumor - metabolism; Chemotherapy; Cyclophosphamide - pharmacology; Dimerization; Doxorubicin - pharmacology; Drug resistance; Drug Resistance, Multiple - drug effects; Drug Resistance, Multiple - physiology; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - physiology; Female; Gene expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gynecology. Andrology. Obstetrics; Humans; Immunoglobulin Fab Fragments - pharmacology; Mammary gland diseases; Medical sciences; Medicine; Medicine & Public Health; Mucin-1 - chemistry; Mucin-1 - genetics; Mucin-1 - immunology; Mucin-1 - physiology; Neoplasm Proteins - chemistry; Neoplasm Proteins - genetics; Neoplasm Proteins - immunology; Neoplasm Proteins - physiology; Oncology; Paclitaxel - pharmacology; Preclinical Study; Protein Processing, Post-Translational; Receptor, ErbB-2 - chemistry; Receptor, ErbB-2 - physiology; RNA, Small Interfering - pharmacology; Signal Transduction - drug effects; Signal Transduction - physiology; Trastuzumab; Tumors; Wnt Proteins - physiology
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-009-0412-3

In the United States, 211,000 women are diagnosed each year with breast cancer. Of the 42,000 breast cancer patients who overexpress the HER2 growth factor receptor,